Study | Regimen | Study design and setting | Number of patients | Overall response rate | Median time to progression/progression-free survival (months) | Median overall survival (months) |
---|---|---|---|---|---|---|
Our study | Nab-paclitaxel 125 mg/m2+ GEM 800 mg/m2, days 1, 8, 15, q4w | Phase II,all lines | 84 | 52.40% | 7.9 | 25.8 |
Gradishar et al. [3] | Nab-paclitaxel 260 mg/m2,q3w | Phase III,all lines | 229 | 33% | 23.0(weeks) | NR |
Paclitaxel 175 mg/m2,q3w | 225 | 19% | 16.9(weeks) | NR | ||
Gradishar et al. [14] | Nab-paclitaxel 300 mg/m2,q3w | Phase II, first-line | 76 | 37% | 11 | 27.7 |
Nab-paclitaxel 100 mg/m2 weekly, days 1, 8, 15, q4w | 76 | 45% | 12.8 | 22.2 | ||
Nab-paclitaxel 150 mg/m2 weekly, days 1, 8, 15, q4w | 74 | 49% | 12.9 | 33.8 | ||
Docetaxel 100 mg/m2,q3w | 74 | 35% | 7.5 | 26.6 | ||
Roy et al. [6] | Nab-paclitaxel 125 mg/m2 weekly, days 1,8,q3w + GEM 1000 mg/m2 weekly, days 1,8,q3w | Phase II, first-line | 50 | 50% | 7.9 | NR |
Lobo et al. [7] | Nab-paclitaxel 150 mg/m2 + GEM 1500 mg/m2 + bevacizumab 10 mg/kg,day 1,15,q4w | Phase II, first-line, TNBC | 30 | 75.90% | 10.4 | NR |
Sun et al. [13] | Nab-paclitaxel 125 mg/m2, days 1, 8, 15+ DDP 75 mg/m2, q4w | Phase II,all lines | 73 | 67.10% | 9.8 | 26.9 |